Company Encyclopedia
View More
name
BioAtla
BCAB.US
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
1.876 T
BCAB.USMarket value -Rank by Market Cap -/-

Financial Score

14/11/2025 Update
D
BiotechnologyIndustry
Industry Ranking296/389
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-813.88%E
    • Profit Margin-541.05%E
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY0.00%C
    • Net Profit YoY43.08%B
    • Total Assets YoY-60.48%E
    • Net Assets YoY-153.38%E
  • Cash ScoreD
    • Cash Flow Margin-18.48%D
    • OCF YoY0.00%C
  • Operating ScoreD
    • Turnover0.23D
  • Debt ScoreE
    • Gearing Ratio161.72%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BioAtla, Inc. Q3 Earnings Call Highlights Progress and Challenges

    BioAtla, Inc.'s Q3 earnings call revealed significant progress in clinical trials and strategic transactions, particularly with FDA alignment on a phase three trial for OPSCC. However, financial challenges persist, with a net loss of $15.8 million and decreased cash reserves. The company is finalizing a strategic transaction and projects substantial market opportunities, despite the financial hurdles. The call highlighted both optimism in clinical advancements and caution due to financial constraints.

    Tip Ranks·
    US
    BCAB
    +28.88%
    Tip Ranks·
    US
    BCAB
    +28.88%

    BioAtla | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    BCAB
    +28.88%
    LB filings·
    US
    BCAB
    +28.88%

    BioAtla Q3 net loss widens to $15.8 mln

    BioAtla's Q3 net loss widened to $15.8 million due to lack of collaboration revenue. R&D expenses decreased from $16.4 million to $9.5 million due to program prioritization and workforce reduction. The company aims to finalize a strategic transaction by year-end. Analysts rate the stock as "buy" with a median price target of $10.00, significantly higher than its current price of $0.69.

    Reuters·
    US
    BCAB
    +28.88%
    Reuters·
    US
    BCAB
    +28.88%

    BioAtla | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    BCAB
    +28.88%
    LB filings·
    US
    BCAB
    +28.88%

    BioAtla Reports Lower Q3 R&D Expenses and Confirms Partnership Plans by Year End

    BioAtla Inc. reported a decrease in Q3 R&D expenses to $9.5 million, down from $16.4 million in 2024, due to reduced program costs and workforce reduction. The company plans to finalize a strategic partnership by year-end and provided updates on clinical trials, including FDA alignment on the Phase 3 Oz-V trial design for OPSCC treatment.

    Reuters·
    US
    BCAB
    +28.88%
    Reuters·
    US
    BCAB
    +28.88%